JPWO2021110561A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021110561A5 JPWO2021110561A5 JP2022533108A JP2022533108A JPWO2021110561A5 JP WO2021110561 A5 JPWO2021110561 A5 JP WO2021110561A5 JP 2022533108 A JP2022533108 A JP 2022533108A JP 2022533108 A JP2022533108 A JP 2022533108A JP WO2021110561 A5 JPWO2021110561 A5 JP WO2021110561A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- agonist
- sequence
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 26
- 102000014150 Interferons Human genes 0.000 claims 25
- 108010050904 Interferons Proteins 0.000 claims 25
- 229940079322 interferon Drugs 0.000 claims 25
- 239000000556 agonist Substances 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 239000000427 antigen Substances 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- 102000025171 antigen binding proteins Human genes 0.000 claims 6
- 108091000831 antigen binding proteins Proteins 0.000 claims 6
- 230000004927 fusion Effects 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 238000001476 gene delivery Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
Claims (16)
(I)アゴニスト抗CD40抗体又はそのアゴニスト抗原結合フラグメント、及び
(II)インターフェロン(IFN)又はその機能的フラグメント
を含むインターフェロン会合抗原結合タンパク質を含む、医薬組成物。 A pharmaceutical composition for use in the treatment of hepatitis B virus (HBV) infection, the composition comprising :
A pharmaceutical composition comprising : (I) an agonist anti-CD40 antibody or agonist antigen-binding fragment thereof; and (II) an interferon-associated antigen-binding protein, including interferon (IFN) or a functional fragment thereof.
(a)配列番号56と少なくとも90%同一である相補性決定領域(CDR)CDRH1、配列番号57と少なくとも90%同一であるCDRH2、及び配列番号58と少なくとも90%同一であるCDRH3を含む、重鎖又はそのフラグメント;並びに
(b)配列番号52と少なくとも90%同一であるCDRL1、配列番号53と少なくとも90%同一であるCDRL2、及び配列番号54と少なくとも90%同一であるCDRL3を含む、軽鎖又はそのフラグメント
を含む、請求項1に記載の医薬組成物。 The agonist anti-CD40 antibody or agonist antigen-binding fragment thereof
(a) a complementarity determining region (CDR) CDRH1 that is at least 90% identical to SEQ ID NO: 56, CDRH2 that is at least 90% identical to SEQ ID NO: 57, and CDRH3 that is at least 90% identical to SEQ ID NO: 58 ; (b) CDRL1 that is at least 90% identical to SEQ ID NO: 52, CDRL2 that is at least 90% identical to SEQ ID NO: 53 , and CDRL3 that is at least 90% identical to SEQ ID NO: 54 ; 2. A pharmaceutical composition according to claim 1, comprising a chain or a fragment thereof.
(a)配列番号56と同一である相補性決定領域(CDR)CDRH1、配列番号57と同一であるCDRH2、及び配列番号58と同一であるCDRH3を含む、重鎖又はそのフラグメント;並びに
(b)配列番号52と同一であるCDRL1、配列番号53と同一であるCDRL2、及び配列番号54と同一であるCDRL3を含む、軽鎖又はそのフラグメント
を含む、
請求項1に記載の医薬組成物。 The agonist anti-CD40 antibody or agonist antigen-binding fragment thereof
(a) a heavy chain or fragment thereof comprising a complementarity determining region (CDR) CDRH1 which is identical to SEQ ID NO: 56, CDRH2 which is identical to SEQ ID NO: 57 , and CDRH3 which is identical to SEQ ID NO: 58; and (b) comprising a light chain or a fragment thereof, comprising CDRL1 identical to SEQ ID NO: 52, CDRL2 identical to SEQ ID NO: 53, and CDRL3 identical to SEQ ID NO: 54;
The pharmaceutical composition according to claim 1.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19306551.3 | 2019-12-03 | ||
EP19306551 | 2019-12-03 | ||
EP19306572 | 2019-12-04 | ||
EP19306572.9 | 2019-12-04 | ||
PCT/EP2020/083737 WO2021110561A1 (en) | 2019-12-03 | 2020-11-27 | Interferon-associated antigen binding proteins for use in treating hepatitis b infection |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023505169A JP2023505169A (en) | 2023-02-08 |
JPWO2021110561A5 true JPWO2021110561A5 (en) | 2023-12-05 |
Family
ID=73554457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022533108A Pending JP2023505169A (en) | 2019-12-03 | 2020-11-27 | Interferon-associated antigen binding protein for use in treating hepatitis B infection |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230028476A1 (en) |
EP (1) | EP4069290A1 (en) |
JP (1) | JP2023505169A (en) |
KR (1) | KR20220109435A (en) |
CN (1) | CN115052626A (en) |
AU (1) | AU2020397416A1 (en) |
BR (1) | BR112022010425A2 (en) |
CA (1) | CA3163356A1 (en) |
IL (1) | IL293449A (en) |
WO (1) | WO2021110561A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL309072A (en) * | 2021-06-09 | 2024-02-01 | Evotec Int Gmbh | Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (en) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | blood substitute |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3675588D1 (en) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE). |
AU6131086A (en) | 1985-07-05 | 1987-01-30 | Whitehead Institute For Biomedical Research | Epithelial cells expressing foreign genetic material |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
WO1989002468A1 (en) | 1987-09-11 | 1989-03-23 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
DE3851153T2 (en) | 1987-12-11 | 1995-01-05 | Whitehead Biomedical Inst | GENETIC MODIFICATION OF ENDOTHELIAL CELLS. |
JP2917998B2 (en) | 1988-02-05 | 1999-07-12 | ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ | Modified hepatocytes and their uses |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1992007943A1 (en) | 1990-10-31 | 1992-05-14 | Somatix Therapy Corporation | Retroviral vectors useful for gene therapy |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
ATE193301T1 (en) | 1993-03-09 | 2000-06-15 | Genzyme Corp | METHOD FOR ISOLATION OF PROTEINS FROM MILK |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
AU2007248628B2 (en) * | 2006-05-03 | 2013-02-07 | The Regents Of The University Of Colorado, A Body Corporate | CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity |
WO2018087345A1 (en) * | 2016-11-14 | 2018-05-17 | F. Hoffmann-La Roche Ag | COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON |
JP2021525761A (en) * | 2018-06-01 | 2021-09-27 | サノフイSanofi | Combination therapy to treat hepatitis B virus infection |
-
2020
- 2020-11-27 US US17/756,797 patent/US20230028476A1/en active Pending
- 2020-11-27 IL IL293449A patent/IL293449A/en unknown
- 2020-11-27 CA CA3163356A patent/CA3163356A1/en active Pending
- 2020-11-27 AU AU2020397416A patent/AU2020397416A1/en active Pending
- 2020-11-27 BR BR112022010425A patent/BR112022010425A2/en unknown
- 2020-11-27 KR KR1020227022257A patent/KR20220109435A/en unknown
- 2020-11-27 JP JP2022533108A patent/JP2023505169A/en active Pending
- 2020-11-27 EP EP20812046.9A patent/EP4069290A1/en active Pending
- 2020-11-27 CN CN202080095495.4A patent/CN115052626A/en active Pending
- 2020-11-27 WO PCT/EP2020/083737 patent/WO2021110561A1/en active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018535650A5 (en) | ||
JP2022079549A5 (en) | ||
HRP20210876T1 (en) | Anti-tmprss2 antibodies and antigen-binding fragments | |
JP2020079252A5 (en) | ||
JP2018521638A5 (en) | ||
JP2012512641A5 (en) | ||
JP2012504955A5 (en) | ||
JP2010516229A5 (en) | ||
JP2018537421A5 (en) | ||
JP2017533694A5 (en) | ||
JP2011528902A5 (en) | ||
JP2011528901A5 (en) | ||
JP2010534478A5 (en) | ||
RU2009136677A (en) | RECOMBINANT ANTIBODIES FOR TREATMENT OF RESPIRATORY SYNCITIAL VIRAL INFECTIONS | |
RU2012112829A (en) | ANTI-GITR-ANTIBODIES | |
JP2006512899A5 (en) | ||
JP2011505867A5 (en) | ||
JP2023071956A5 (en) | ||
JP2017537084A5 (en) | ||
JP2018520334A5 (en) | ||
JP2008532559A5 (en) | ||
RU2018126318A (en) | POLYSPECIFIC ANTIBODIES MOLECULES HAVING SPECIFICITY FOR TNF-ALPHA, IL-17A AND IL-17F | |
JP2018514193A5 (en) | ||
JP2018522540A5 (en) | ||
JP2024016201A5 (en) |